2026-04-13T07:40:09Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4689752026-03-28T08:47:37Zcom_2072_98col_2072_378192

00925njm 22002777a 4500 dc Petazzi, Paolo author Miquel-Serra, Laia author Huertas, Sergio author González, Cecilia author Boto, Neus author Muñiz-Diaz, Eduardo author Menéndez Bujan, Pablo author Sevilla, Ana author Nogues Galvez, Nuria author Universitat Autònoma de Barcelona author 2022 The limited availability of red cells with extremely rare blood group phenotypes is one of the global challenges in transfusion medicine that has prompted the search for alternative self-renewable pluripotent cell sources for the in vitro generation of red cells with rare blood group types. One such phenotype is the Rh, which lacks all the Rh antigens on the red cell membrane and represents one of the rarest blood types in the world with only a few active blood donors available worldwide. Rh red cells are critical for the transfusion of immunized patients carrying the same phenotype, besides its utility in the diagnosis of Rh alloimmunization when a high-prevalence Rh specificity is suspected in a patient or a pregnant woman. In both scenarios, the potential use of human-induced pluripotent stem cell (hiPSC)-derived Rh red cells is also dependent on ABO compatibility. Here, we present a CRISPR/Cas9-mediated ABO gene edition strategy for the conversion of blood type A to universal type O, which we have applied to an Rh donor-derived hiPSC line, originally carrying blood group A. This work provides a paradigmatic example of an approach potentially applicable to other hiPSC lines derived from rare blood donors not carrying blood type O. ABO CRISPR Gene edition Ipsc Rare blood groups Rh Transfusion medicine ABO gene editing for the conversion of blood type A to universal type O in Rh donor-derived human-induced pluripotent stem cells